組換えヒトインスリン製造

バイオテクノロジーと医薬品製造の融合

Pharmaceutical & Drug Manufacturing Global Industrial Scale $35 billion

概要

Recombinant human insulin is produced using genetically engineered Escherichia coli or Saccharomyces cerevisiae that express the human insulin gene. This biotechnological process replaced the previous method of extracting insulin from pig and cow pancreases, providing unlimited supply with reduced immunogenicity. The process involves fermentation, cell lysis, inclusion body solubilization, refolding, enzymatic modification, and multi-step chromatographic purification to produce pharmaceutical-grade insulin.

化学プロセス

E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by reversed-phase and ion-exchange chromatography.

Proinsulin →[Trypsin + Carboxypeptidase B] Insulin (A-chain + B-chain linked by disulfide bonds) + C-peptide

原材料

  • Glucose (C₆H₁₂O₆) — Corn processing (Carbon source for fermentation)
  • Ammonium sulfate ((NH₄)₂SO₄) — Chemical synthesis (Nitrogen source)
  • Trypsin (enzyme) — Recombinant production (C-peptide cleavage)

最終製品

  • Recombinant human insulin — Diabetes treatment (>98% purity, multiple analog forms)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annually.

安全性の考慮事項

最新のイノベーション

Insulin analogs (lispro, glargine, aspart) with modified amino acid sequences provide faster or longer-acting profiles.
Cell-free protein synthesis and oral insulin delivery systems are in advanced development stages.

もっと見る Pharmaceutical & Drug Manufacturing

アモキシシリン半合成製造

Global Industrial Scale

イブプロフェン合成 — BHCグリーンプロセス

Global Industrial Scale

サリチル酸のアセチル化によるアスピリン合成

Global Industrial Scale

パラセタモール（アセトアミノフェン）合成

Global Industrial Scale

プロトンポンプ阻害剤オメプラゾール合成

Global Industrial Scale

塩酸メトホルミン合成

Global Industrial Scale

発酵によるペニシリンG製造

Global Industrial Scale

Frequently Asked Questions

What industry uses 組換えヒトインスリン製造?
組換えヒトインスリン製造 is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in 組換えヒトインスリン製造?
E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by rev
What is the economic significance of 組換えヒトインスリン製造?
組換えヒトインスリン製造 has a market value of $35 billion.
What is the environmental impact of 組換えヒトインスリン製造?
Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annua
What raw materials are used in 組換えヒトインスリン製造?
The main raw materials include: Glucose (C₆H₁₂O₆), Ammonium sulfate ((NH₄)₂SO₄), Trypsin (enzyme).